In last trading session, Monte Rosa Therapeutics Inc (NASDAQ:GLUE) saw 0.79 million shares changing hands with its beta currently measuring 1.32. Company’s recent per share price level of $9.26 trading at -$0.27 or -2.83% at ring of the bell on the day assigns it a market valuation of $568.31M. That closing price of GLUE’s stock is at a discount of -33.91% from its 52-week high price of $12.40 and is indicating a premium of 68.57% from its 52-week low price of $2.91. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 11.23 million shares which gives us an average trading volume of 2.05 million if we extend that period to 3-months.
For Monte Rosa Therapeutics Inc (GLUE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.46 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
Upright in the red during last session for losing -2.83%, in the last five days GLUE remained trading in the green while hitting it’s week-highest on Friday, 11/08/24 when the stock touched $9.26 price level, adding 5.99% to its value on the day. Monte Rosa Therapeutics Inc’s shares saw a change of 63.89% in year-to-date performance and have moved 4.04% in past 5-day. Monte Rosa Therapeutics Inc (NASDAQ:GLUE) showed a performance of 91.32% in past 30-days. Number of shares sold short was 5.23 million shares which calculate 8.36 days to cover the short interests.
Monte Rosa Therapeutics Inc (GLUE) estimates and forecasts
Statistics highlight that Monte Rosa Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 90.93% of value to its shares in past 6 months, showing an annual growth rate of 30.42% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.82M for the same. And 2 analysts are in estimates of company making revenue of 2.5M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -96.71% during past 5 years.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Insiders are in possession of 0.71% of company’s total shares while institution are holding 84.17 percent of that, with stock having share float percentage of 84.77%. Investors also watch the number of corporate investors in a company very closely, which is 84.17% institutions for Monte Rosa Therapeutics Inc that are currently holding shares of the company. NEA MANAGEMENT COMPANY, LLC is the top institutional holder at GLUE for having 7.69 million shares of worth $28.77 million. And as of 2024-06-30, it was holding 12.7872 of the company’s outstanding shares.
The second largest institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, which was holding about 5.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.9368 of outstanding shares, having a total worth of $22.36 million.
